VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Vaxart, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$0.48+0.02 (+5.04%)

Close on Oct 19, 2026

Market cap: $115.15M
P/E (TTM): 3.2
Dividend yield: –

Vaxart, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30	FY 2009 2009-12-26
Depreciation & Amortization	8.58	8.85	8.62	5.81	4.21	2.71	3.60	3.20	0.10	1.10	2.40	3.00	3.10	0.50
Stock-Based Compensation	8.31	12	14	14	8.87	4.36	0.63	0.54	2.00	2.10	1.70	2.60	0.50	2.46
Deferred Income Taxes	0	0	0	0	0	0	0	–	–	–	–	–	-0.20	–
Change in Accounts Receivable	-8.80	-2.75	-2.99	0.05	0.26	3.29	-1.82	14	12	6.20	-7.10	-4.20	-3.40	-6.69
Change in Accounts Payable	15	5.27	-2.44	0.36	1.63	1.21	-0.06	-3.78	-0.70	-16	11	2.80	2.90	–
Change in Unearned Revenue	–	–	-2.00	2.00	0	–	–	–	–	–	-0.30	-0.10	0.20	18
Operating Cash Flow	7.71	-45	-70	-95	-60	-24	-13	-15	-14	-9.60	-3.30	-14	-16	6.22
Capital Expenditures	-0.15	-0.55	-1.87	-9.60	-5.16	-1.22	-0.85	-0.71	-0.20	-0.10	-0.10	-1.00	-1.30	0.00
Acquisitions	–	–	–	0	-4.83	–	–	-0.02	–	-8.90	–	–	–	–
Sale of Property, Plant & Equipment	0.01	0	0.12	0	0	0.00	0	–	–	0.40	–	–	–	–
Purchase of Investments	-23	-64	-27	-55	-45	0	0	-0.57	-15	-18	-10	–	–	-91
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	56
Investing Cash Flow	17	-21	44	-20	-49	-1.22	-0.85	26	1.30	-19	-10	32	-1.30	-36
Share Repurchases	–	–	–	–	–	–	–	–	–	–	–	–	-0.40	-7.94
Stock Issued	–	–	–	17	122	9.18	2.54	–	–	–	27	27	–	0.53
Taxes Paid on Share-Based Awards	-0.20	-0.21	-0.37	0	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	4.24	57	15	17	126	138	16	-1.73	18	-0.10	27	–	-0.40	-18
Foreign Exchange Rate Adjustments	–	–	–	–	–	–	–	–	–	-7.90	1.50	-4.80	-2.80	–
Net Change in Cash	29	-9.53	-11	-98	17	113	2.02	9.94	5.00	-29	13	18	-18	-47
Free Cash Flow	7.57	-45	-72	-104	-65	-25	-14	-15	-14	-9.70	-3.40	-15	-17	6.21
Income Taxes Paid	0.10	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest Paid	–	–	–	–	0	0	0.23	0.36	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 16.3%
Net margin: 15.9%
Return on equity, FY2025: 22.3%

Financial strength

Current ratio: 1.60
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 69.7%

Valuation

P/E ratio: 3.2
Price to sales: 0.47
Price to book: 1.40
Dividend yield: –